Total Payments
$194,663
2024 Payments
$39,038
Companies
87
Transactions
1,017
Medicare Patients
6,045
Medicare Billing
$1.9M
Payment Breakdown by Category
Other$141,799 (72.8%)
Food & Beverage$24,688 (12.7%)
Travel$17,914 (9.2%)
Consulting$9,863 (5.1%)
Education$399.39 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $140,351 | 41 | 72.1% |
| Food and Beverage | $24,688 | 881 | 12.7% |
| Travel and Lodging | $17,914 | 63 | 9.2% |
| Consulting Fee | $9,863 | 6 | 5.1% |
| Long term medical supply or device loan | $1,098 | 12 | 0.6% |
| Education | $399.39 | 13 | 0.2% |
| Grant | $350.00 | 1 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $102,688 | 199 | $0 (2024) |
| Gilead Sciences, Inc. | $54,936 | 60 | $0 (2024) |
| PFIZER INC. | $11,357 | 81 | $0 (2024) |
| PUMA BIOTECHNOLOGY, INC. | $3,474 | 19 | $0 (2024) |
| Daiichi Sankyo Inc. | $3,465 | 28 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $2,483 | 77 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $2,453 | 35 | $0 (2024) |
| Roche Products Limited | $1,824 | 3 | $0 (2019) |
| Celgene Corporation | $1,417 | 17 | $0 (2023) |
| Janssen Biotech, Inc. | $1,109 | 53 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $39,038 | 140 | Gilead Sciences, Inc. ($33,044) |
| 2023 | $14,720 | 91 | Gilead Sciences, Inc. ($11,251) |
| 2022 | $12,604 | 76 | Gilead Sciences, Inc. ($10,604) |
| 2021 | $4,600 | 5 | PFIZER INC. ($4,410) |
| 2020 | $2,157 | 67 | Daiichi Sankyo Inc. ($976.06) |
| 2019 | $26,169 | 165 | Novartis Pharmaceuticals Corporation ($19,737) |
| 2018 | $35,311 | 224 | Novartis Pharmaceuticals Corporation ($26,805) |
| 2017 | $60,063 | 249 | Novartis Pharmaceuticals Corporation ($51,970) |
All Payment Transactions
1,017 individual payment records from CMS Open Payments — Page 1 of 41
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Genentech USA, Inc. | Itovebi (Biological) | Food and Beverage | In-kind items and services | $20.55 | General |
| Category: BioOncology | ||||||
| 12/11/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $125.33 | General |
| Category: Oncology | ||||||
| 12/10/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| Category: Oncology | ||||||
| 12/10/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $56.58 | General |
| Category: ONC | ||||||
| 12/09/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $22.12 | General |
| Category: Oncology | ||||||
| 12/04/2024 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $20.47 | General |
| Category: ONCOLOGY | ||||||
| 12/03/2024 | Lilly USA, LLC | VERZENIO (Drug), JAYPIRCA | Food and Beverage | In-kind items and services | $24.24 | General |
| Category: Oncology | ||||||
| 12/02/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $27.35 | General |
| Category: Oncology | ||||||
| 11/26/2024 | ABBVIE INC. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $30.74 | General |
| Category: ONCOLOGY | ||||||
| 11/25/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $22.24 | General |
| Category: ONCOLOGY | ||||||
| 11/22/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological), ZEJULA | Food and Beverage | In-kind items and services | $23.49 | General |
| Category: ONCOLOGY | ||||||
| 11/20/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $21.73 | General |
| Category: Oncology | ||||||
| 11/14/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| Category: Oncology | ||||||
| 11/13/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), LYNPARZA | Food and Beverage | In-kind items and services | $28.49 | General |
| Category: ONCOLOGY | ||||||
| 11/11/2024 | ADC Therapeutics America, Inc. | — | Food and Beverage | In-kind items and services | $21.16 | General |
| 11/06/2024 | ABBVIE INC. | ELAHERE (Drug) | Food and Beverage | In-kind items and services | $34.09 | General |
| Category: ONCOLOGY | ||||||
| 11/06/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $6.97 | General |
| Category: Oncology | ||||||
| 11/05/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $13.78 | General |
| Category: Oncology | ||||||
| 11/04/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $26.20 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 10/30/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $28.67 | General |
| Category: ONCOLOGY | ||||||
| 10/28/2024 | BeiGene USA, Inc. | TEVIMBRA (Drug) | Food and Beverage | In-kind items and services | $20.36 | General |
| Category: Oncology | ||||||
| 10/23/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $15.05 | General |
| Category: Oncology | ||||||
| 10/21/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $30.23 | General |
| 10/17/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| Category: Oncology | ||||||
| 10/16/2024 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $21.48 | General |
| Category: CELLT | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 33 | 1,748 | 74,238 | $2.1M | $677,194 |
| 2022 | 28 | 1,442 | 35,565 | $1.8M | $564,730 |
| 2021 | 28 | 1,410 | 32,695 | $1.5M | $418,135 |
| 2020 | 28 | 1,445 | 19,093 | $957,420 | $276,349 |
Total Patients
6,045
Total Services
161,591
Medicare Billing
$1.9M
Procedure Codes
137
All Medicare Procedures & Services
137 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 12 | 7,400 | $762,200 | $319,528 | 41.9% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 39 | 7,200 | $302,400 | $129,018 | 42.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 297 | 634 | $274,522 | $62,751 | 22.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 272 | 482 | $156,650 | $34,840 | 22.2% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 66 | 259 | $136,234 | $28,666 | 21.0% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 13 | 11,100 | $77,700 | $26,300 | 33.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 57 | 57 | $34,713 | $8,779 | 25.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 42 | 42 | $31,080 | $7,558 | 24.3% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 42 | 475 | $28,975 | $6,243 | 21.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 86 | 88 | $26,755 | $5,361 | 20.0% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 22 | 84 | $21,336 | $4,648 | 21.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 99 | 104 | $22,880 | $4,536 | 19.8% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2023 | 14 | 12,240 | $24,480 | $4,443 | 18.1% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 37 | 70 | $18,270 | $3,810 | 20.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 21 | 23 | $11,086 | $2,550 | 23.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 14 | 16 | $9,696 | $2,382 | 24.6% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 23 | 95 | $10,450 | $2,214 | 21.2% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 19 | 20 | $8,860 | $2,213 | 25.0% |
| 96374 | Injection of drug or substance into vein | Office | 2023 | 44 | 71 | $10,295 | $2,157 | 20.9% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 73 | 183 | $8,784 | $2,078 | 23.7% |
| J1756 | Injection, iron sucrose, 1 mg | Office | 2023 | 21 | 11,000 | $11,000 | $1,805 | 16.4% |
| 96523 | Irrigation of implanted venous access drug delivery device | Office | 2023 | 33 | 85 | $8,755 | $1,710 | 19.5% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 16 | 65 | $7,345 | $1,598 | 21.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 12 | 12 | $6,732 | $1,554 | 23.1% |
| 96360 | Infusion into a vein for hydration, 31-60 minutes | Office | 2023 | 24 | 54 | $6,858 | $1,393 | 20.3% |
About Dr. David Riseberg, MD
Dr. David Riseberg, MD is a Medical Oncology healthcare provider based in Baltimore, Maryland. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/20/2006. The National Provider Identifier (NPI) number assigned to this provider is 1124133210.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Riseberg, MD has received a total of $194,663 in payments from pharmaceutical and medical device companies, with $39,038 received in 2024. These payments were reported across 1,017 transactions from 87 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($140,351).
As a Medicare-enrolled provider, Riseberg has provided services to 6,045 Medicare beneficiaries, totaling 161,591 services with total Medicare billing of $1.9M. Data is available for 4 years (2020–2023), covering 137 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location Baltimore, MD
- Active Since 08/20/2006
- Last Updated 07/08/2007
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1124133210
Products in Payments
- KISQALI (Drug) $97,601
- Trodelvy (Drug) $54,779
- IBRANCE (Drug) $10,357
- PIQRAY (Drug) $3,787
- Nerlynx (Drug) $3,231
- Non-Covered Product (Drug) $1,824
- OPDIVO (Biological) $1,762
- IMFINZI (Biological) $1,388
- Abraxane (Drug) $1,221
- Enhertu (Drug) $1,079
- IMBRUVICA (Drug) $636.51
- KEYTRUDA (Biological) $372.17
- DARZALEX (Biological) $323.39
- JAKAFI (Drug) $319.45
- XTANDI (Drug) $265.01
- GILOTRIF (Drug) $256.23
- AFINITOR (Drug) $233.44
- INTERA (Device) $228.15
- LYNPARZA (Drug) $221.87
- BRUKINSA (Drug) $220.82
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Baltimore
Mario Eisenberger, M.d, M.D
Medical Oncology — Payments: $2.9M
Medical Oncology $2.9M
Dr. Tanguy Seiwert, M.d, M.D
Medical Oncology — Payments: $622,422
Medical Oncology $622,422
Carole Miller, Md, MD
Medical Oncology — Payments: $587,841
Medical Oncology $587,841
Bruce Smith, M.d, M.D
Medical Oncology — Payments: $406,689
Medical Oncology $406,689
Carol Huff, M.d, M.D
Medical Oncology — Payments: $384,580
Medical Oncology $384,580
Leisha Emens
Medical Oncology — Payments: $252,501
Medical Oncology $252,501